At a glance
ClinicalIndex Comparison RecordPhase 2Active· 68 target
Drug / intervention
PD-1 blocking antibody +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PD-1 Antibody Combined With Chemotherapy in High-risk Recurrent Nasopharyngeal Carcinoma: a Prospective, Open, Single-arm Phase II Clinical Trial
In Brief
A Phase 2 clinical trial evaluating PD-1 blocking antibody, Chemotherapy, and 1 other intervention for Recurrent Nasopharyngeal Carcinoma. Active but no longer recruiting, targeting 68 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
This is a a prospective, single-arm phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemotherapy in high-risk recurrent nasopharyngeal carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Nasopharyngeal Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 2ActiveOverdue
2020202120222023202420252026
First PostedApr 2019
Enrollment StartMar 2020
Primary CompletionNov 2023
Study CompletionMay 2026
TodayJul 2026
First PostedApr 29, 2019
Enrollment StartMar 12, 2020
Primary CompletionNov 22, 2023
Study CompletionMay 1, 2026
TodayJul 1, 2026
Enrollment to primary: 3.7 yearsPosted 7.2 years ago
Interventions
PD-1 blocking antibodydrug
Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.
Chemotherapydrug
Cisplatin and Gemcitabine
IMRTradiation
IMRT 60-66Gy, 1.8-2.0Gy/f/day